Trelegy Ellipta (fluticasone furoate/ umeclidinium/vilanterol [as trifenatate])
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
Get access to exclusive events on the topics that matter to you, free patient resources including patient support materials, demo devices and updates on the latest in HIV/AIDS, respiratory, oncology and Vaccines
Abbreviations
FEV1, forced expiratory volume in one second; FF, fluticasone furoate; ICS, inhaled corticosteroid; LABA, long-acting ß2-agonist; LAMA, long-acting muscarinic antagonist; OD, once-daily; UMEC, umeclidinium; VI, vilanterol
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Trade marks are owned by or licensed to the GSK group of companies.
PM-IE-NA-WCNT-220009 Date of Preparation: August 2023